新型自动化免疫检测血清NY-ESO-1和XAGE1抗体联合预测非小细胞肺癌抗PD-1治疗反应
该研究开发了基于HISCL™的全自动化学发光酶免疫分析法,检测非小细胞肺癌患者血清中NY-ESO-1和XAGE1抗体。在30例接受抗PD-1单药治疗的患者中,联合检测两种抗体的AUROC最高达0.91(95%CI 0.78-1.0),表明该自动化免疫检测系统有助于预测免疫检查点治疗的临床获益。
要点
- HISCL™自动化免疫检测可稳定、特异地测定血清NY-ESO-1/XAGE1抗体。
- 联合检测NY-ESO-1/XAGE1抗体预测抗PD-1治疗反应的AUROC为0.91。
- 该检测系统有望用于筛选可从抗PD-1单药治疗中获益的NSCLC患者。
核心结论
- 全自动免疫检测系统可有效预测NSCLC患者接受免疫检查点治疗的临床获益。
研究设计与样本
- 研究纳入30例接受抗PD-1单药治疗前的NSCLC患者血清,采用HISCL™全自动化学发光酶免疫分析法检测NY-ESO-1/XAGE1抗体,并评估抗体稳定性、干扰因素及预测反应准确性(AUROC)。
主要发现
- HISCL检测的NY-ESO-1/XAGE1抗体水平与ELISA高度相关,且在四种温度、五次冻融循环及长期储存下稳定,不受常见血液成分干扰。
- 15例抗PD-1单药治疗应答者的抗体水平显著高于非应答者和健康供者。
- 联合检测NY-ESO-1/XAGE1抗体的AUROC最高,为0.91(95%CI 0.78-1.0)。
关键数值与推荐
- 联合预测抗PD-1治疗反应的AUROC为0.91(95%CI 0.78-1.0)。
临床怎么用
- 该自动化免疫检测可用于治疗前评估NSCLC患者抗PD-1单药治疗的潜在获益。
局限性
- 研究样本量较小(30例NSCLC患者),需更大规模验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anti-programmed cell death-1 (PD-1) antibodies (Abs) are key drugs in non-small-cell lung cancer (NSCLC) treatment; however, clinical benefits with anti-PD-1 monotherapy are limited. We reported that serum Abs against cancer-testis antigens NY-ESO-1 and XAGE1 predicted clinical benefits. We aimed to develop a fully automated immunoassay system measuring NY-ESO-1/XAGE1 Abs. METHODS: Sera from 30 NSCLC patients before anti-PD-1 monotherapy were reacted with recombinant NY-ESO-1 protein- or synthetic XAGE1 peptide-coated magnetic beads. ALP-conjugated Ab and chemiluminescent substrate were added and luminescence measured. These procedures were automated using high sensitivity chemiluminescent enzyme immunoassay (HISCL™). NY-ESO-1/XAGE1 Ab stability was tested under various conditions. Response prediction accuracy was evaluated using area under receiver operating curve (AUROC). RESULTS: HISCL detected specific serum NY-ESO-1/XAGE1 Abs, which levels in ELISA and HISCL were highly correlated. The Ab levels in HISCL were stable at four temperatures, five freeze/thaw cycles, and long-term storage; the levels were not interfered by common blood components. The Ab levels in 15 NSCLC responders to anti-PD-1 monotherapy were significantly higher than those in non-responders and healthy donors. The AUROC was the highest (0.91; 95% CI, 0.78-1.0) in combinatory prediction with NY-ESO-1/XAGE1 Abs. CONCLUSION: Our immunoassay system is useful to predict clinical benefits with NSCLC immune-checkpoint therapy.
引用
- Sakai Y, Kurose K, Sakaeda K, et al. A novel automated immunoassay for serum NY-ESO-1 and XAGE1 antibodies in combinatory prediction of response to anti-programmed cell death-1 therapy in non-small-cell lung cancer. Clin Chim Acta. 2021. PMID: 33865813. doi:10.1016/j.cca.2021.04.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。